Vaccines for seasonal and pandemic influenza

被引:184
作者
Nichol, Kristin L.
Treanor, John J.
机构
[1] Univ Rochester, Med Ctr, Infect Dis Unit, Rochester, NY 14642 USA
[2] Univ Minnesota, Minneapolis, MN USA
[3] Minneapolis VA Med Ctr, Minneapolis, MN USA
关键词
D O I
10.1086/507544
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Seasonal influenza continues to have a huge annual impact in the United States, accounting for tens of millions of illnesses, hundreds of thousands of excess hospitalizations, and tens of thousands of excess deaths. Vaccination remains the mainstay for the prevention of influenza. In the United States, 2 types of influenza vaccine are currently licensed: trivalent inactivated influenza vaccine and live attenuated influenza vaccine. Both are safe and effective in the populations for which they are approved for use. Children, adults < 65 years of age, and the elderly all receive substantial health benefits from vaccination. In addition, vaccination appears to be cost-effective, if not cost saving, across the age spectrum. Despite long-standing recommendations for the routine vaccination of persons in high-priority groups, US vaccination rates remain too low across all age groups. Important issues to be addressed include improving vaccine delivery to current and expanded target groups, ensuring timely availability of adequate vaccine supply, and development of even more effective vaccines. Development of a vaccine against potentially pandemic strains is an essential part of the strategy to control and prevent a pandemic outbreak. The use of existing technologies for influenza vaccine production would be the most straightforward approach, because these technologies are commercially available and licensing would be relatively simple. Approaches currently being tested include subvirion inactivated vaccines and cold-adapted, live attenuated vaccines. Preliminary results have suggested that, for some pandemic antigens, particularly H5, subvirion inactivated vaccines are poorly immunogenic, for reasons that are not clear. Data from evaluation of live pandemic vaccines are pending. Second-generation approaches designed to provide improved immune responses at lower doses have focused on adjuvants such as alum and MF59, which are currently licensed for influenza or other vaccines. Additional experimental approaches are required to achieve the ultimate goal for seasonal and pandemic influenza prevention-namely, the ability to generate broadly cross-reactive and durable protection in humans.
引用
收藏
页码:S111 / S118
页数:8
相关论文
共 46 条
  • [1] ADAMS PF, 1996, VITAL HLTH STAT, V10, P1
  • [2] [Anonymous], COCHRANE DATABASE SY, DOI DOI 10.1002/14651858.CD001269.PUB2.ART
  • [3] Serum antibody responses after intradermal vaccination against influenza
    Belshe, RB
    Newman, FK
    Cannon, J
    Duane, C
    Treanor, J
    Van Hoecke, C
    Howe, BJ
    Dubin, G
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (22) : 2286 - 2294
  • [4] Promises and challenges of live-attenuated intranasal influenza vaccines across the age spectrum: a review
    Boyce, TG
    Poland, GA
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2000, 54 (04) : 210 - 218
  • [5] Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine:: phase I randomised trial
    Bresson, Jean-Louis
    Perronne, Christian
    Launay, Odile
    Gerdil, Catherine
    Saville, Melanie
    Wood, John
    Hoeschler, Katja
    Zambon, Maria C.
    [J]. LANCET, 2006, 367 (9523) : 1657 - 1664
  • [6] Vaccinating healthcare workers against influenza to protect the vulnerable - Is it a good use of healthcare resources? A systematic review of the evidence and an economic evaluation
    Burls, A
    Jordan, R
    Barton, P
    Olowokure, B
    Wake, B
    Albon, E
    Hawker, J
    [J]. VACCINE, 2006, 24 (19) : 4212 - 4221
  • [7] Effects of influenza vaccination of health-care workers on mortality of elderly people in long-term care: a randomised controlled trial
    Carman, WF
    Elder, AG
    Wallace, LA
    McAulay, K
    Walker, A
    Murray, GD
    Stott, DJ
    [J]. LANCET, 2000, 355 (9198) : 93 - 97
  • [8] Center for Disease Control and Prevention, PREV FLU
  • [9] Euler G. L., 2005, Morbidity and Mortality Weekly Report, V54, P304
  • [10] Fauci AS, 2006, EMERG INFECT DIS, V12, P73